REFERENCES
- Boswell FJ, Ashby JP, Andrews JM, Wise R. Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. Antimicrob Chemother 2002; 50: 525–532.
- Craig WA, Andes DR. In vivo pharmacodynamic activity of faropenem against Streptococcus pneumoniae. Abstracts of the 41” Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001, Chicago, Abstract A-2094, p34.
- Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42: 2375–2379.
- Lovering AM, White LO, Lewis DA, MacGowan AP, Routh KR, Pickin DM, Reeves DS. Pharmacokinetics of FCE 22101 in man following different modes of administration. Antimicrob Chemother 1989; 23, Supplement C: 179–196.
- Fuhst C, Barger A, Wiegand I, Wiedeman B. The impact of protein binding of faropenem on its antibiotic activity. Clin Microbiol Infect 2002; 8, Supplement 1: Abstract P-1395, p328.
- National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard 5th Edition M7-A5, Wayne, PA, USA.
- Black JA, Moland ES, Chartrand SA, Thomson KS. In vitro activity of faropenem against 181 isolates of antibiotic resistant Streptococcus pneumoniae. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000; Ontario. Abstract 365, p160.
- Felmingham D, Robbins MJ, Mathias I, Tsa N, Baker I, Dalhoff A. In vitro activity of faropenem, an oral penem. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000; Ontario. Abstract 361, p159.
- Von Eiff C, Schepers S, Peters S. Comparative in vitro activity of faropenem against Staphylococci. Abstracts of the 41” Interscience Conference on Antimicrobial Agents and Chemotherapy 2001; Chicago, E-798, p184.
- Schubert S, Ullman U, Dalhoff A. Influence of sucrose and human serum on the activity of faropenem and amoxi-cillin against Streptococcus pneumoniae. Abstracts of the 41” Interscience Conference on Antimicrobial Agents and Chemotherapy 2001; Abstract 2078, p30.
- Schmidt A, Ammelung P, Bach R, Morciszek D, Labischinski H, Dalhoff A. Activity of faropenem against Streptococcus pneumoniae under in vitro test conditions that mimic pharmacokinetic properties in man. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000; Abstract 498, p159.
- Gustafsson I, Cars O. The influence of protein binding on the effect of faropenem against H. influenzae, Clin Microbiol Infect 2002; 8, Supplement 1: Abstract P1390, p326.